Stock Market News
Shire gets FDA approval for technology transfer of Cinryze drug
Shire has received approval from the US Food and Drug Administration for the technology transfer of its Cinryze drug product manufacturing process to its site in Vienna, Austria.
The biotechnology company will begin commercial manufacturing of Cinryze - an injectable medicine used to help prevent swelling and/or painful attacks in teenagers and adults with hereditary angioedema (HAE) - in the first quarter of this year.
Matt Walker, head of technical operations, said: "With the FDA's approval of the tech transfer, we are pleased to strengthen our supply reliability for adult and adolescent HAE patients who count on Cinryze to help prevent attacks."
HAE is a rare genetic disorder that is thought to affect between 1 in 10,000 and 1 in 50,000 people in the world and according to Shire, Cinryze is one of the leading therapies approved for its treatment in adolescent and adult patients. The medicine can help reduce how often attacks occur, how severe they are, and how long they last.
HAE can cause swelling attacks in any part of the body, but the most common locations include the abdomen, face, feet, genitals, hands and throat.
At 1300 GMT, the shares were down 0.8% to 3,482p.
The biotechnology company will begin commercial manufacturing of Cinryze - an injectable medicine used to help prevent swelling and/or painful attacks in teenagers and adults with hereditary angioedema (HAE) - in the first quarter of this year.
Matt Walker, head of technical operations, said: "With the FDA's approval of the tech transfer, we are pleased to strengthen our supply reliability for adult and adolescent HAE patients who count on Cinryze to help prevent attacks."
HAE is a rare genetic disorder that is thought to affect between 1 in 10,000 and 1 in 50,000 people in the world and according to Shire, Cinryze is one of the leading therapies approved for its treatment in adolescent and adult patients. The medicine can help reduce how often attacks occur, how severe they are, and how long they last.
HAE can cause swelling attacks in any part of the body, but the most common locations include the abdomen, face, feet, genitals, hands and throat.
At 1300 GMT, the shares were down 0.8% to 3,482p.
Related share prices |
---|
Shire Plc (SHP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price